A
Advanced NanoTherapies
Drug-coated balloons engineered to deliver stent-like patency and restenosis prevention with long-term release of synergistic drugs
About Advanced NanoTherapies
Advanced NanoTherapies, Inc. is a pioneering company in the medical technology sector, specializing in nanoparticle drug delivery systems. The company focuses on developing advanced therapeutic solutions for coronary artery disease (CAD) and peripheral artery disease (PAD). Their flagship product, SirPlux Duo DCB, is engineered to deliver two synergistic drugs, Sirolimus and Paclitaxel, simultaneously. This innovative approach aims to inhibit cell growth at a higher potency and lower dosage compared to existing treatments, offering a next-generation front-line therapy for cardiovascular conditions.
Read full description
The company operates primarily in the healthcare and medical technology markets, targeting hospitals, clinics, and medical professionals specializing in cardiovascular treatments. Their business model revolves around the development and eventual commercialization of their proprietary drug delivery platforms. Although their products are currently in the development phase and not yet available for sale, the company plans to generate revenue through product sales, licensing agreements, and potential partnerships with larger pharmaceutical companies.
Advanced NanoTherapies leverages its A.N.T. nanoparticle platform to provide sustained drug release and retention in tissue, resulting in stent-like patency and improved restenosis prevention. The platform is drug-agnostic, meaning it can be adapted for use with various drug combinations, making it versatile for multiple medical applications beyond cardiovascular treatments, including neurology, ENT, and orthopedics.
At a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Mountain View, United States
- Employees
- 21
- Open positions
- None listed
- Dealroom signal
- 85.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, DT and LS, science-based
- Technology
- Nanotech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Advanced NanoTherapies.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jun 2026 | $31M | $124M | S3 Ventures | ↗ |
| SERIES A✓Equity / VC | Aug 2023 | $4M | $36M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Advanced NanoTherapies is 640 monthly website visits, up 300% over the last three months. Advanced NanoTherapies's team grew 31.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
- FVForMED Ventures
Cleveland Clinic
Series A1 investor entered at this stage
S3 Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Advanced NanoTherapies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Advanced NanoTherapies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.